Incyte Corp. — Sponsor Intelligence | 59 EU Trials

Filter these 59 trials by condition, phase, country and more.

Open in Search →

59 Registered trials

22 Recruiting

34 Completed trials

21 Countries active

49 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I

Phase III: 28 Phase II/III: 1 Phase II: 16 Phase I/II: 4 Phase I: 6 Phase I (Other): 4

Oversight events:

4 temporary halts across 1 trial

View oversight register →

100%

34 of 34 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Vitiligo 5 Chronic graft versus host disease 5 Myelofibrosis 3 Non-small cell lung cancer 3 Malignant melanoma stage IV 3 Non-small cell lung cancer stage IV 3 Diffuse large B-cell lymphoma 3 Metastatic malignant melanoma 3 Non-small cell lung cancer metastatic 3 Hepatocellular carcinoma 2 Ovarian cancer 2 Myeloproliferative neoplasm 2

Top IMPs

RUXOLITINIB 12 4-[3-(CYANOMETHYL)-3-(3',5'-DIMETHYL-1H,1'H-[4,4'-BIPYRAZOL]-1-YL)AZETIDIN-1-YL]-2,5-DIFLUORO-N-[(2S)-1,1,1-TRIFLUOROPROPAN-2-YL]BENZAMIDE 7 TAFASITAMAB 7 POVORCITINIB 5 AXATILIMAB 4 INCB099280 4 RETIFANLIMAB 4 LENALIDOMIDE 3 PEMIGATINIB 3 8-ETHOXY-N-((3R,4S)-3-METHYL-1-(METHYLSULFONYL)PIPERIDIN-4-YL)-7-(1H-PYRAZOL-4-YL)-[1,2,4]TRIAZOLO[1,5-A]PYRIDIN-2-AMINE 2 CARBOPLATIN 2 CISPLATIN 2

All trials — page 3

59 total

A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (S… Ended

2022-501753-36-00 Phase III 7 countries 4-[3-(CYANOMETHYL)-3-(3',5'-DIMETHYL-1H,1'H-[4,4'-BIPYRAZOL]-1-YL)AZETIDIN-1-YL]…
INCA 32459-101: A Phase 1, Open-Label, Multicenter Study of INCA32459 in Participants With Select Advanced Malignancies Ended

2022-501505-13-00 Phase I 4 countries
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti–LAG-3) and INCAGN02390 (Anti–TI… Ended

2023-504270-38-00 Phase II 5 countries HUMAN IGG1K MONOCLONAL ANTIBODY AGAINST TIM-3; RETIFANLIMAB; TUPARSTOBART
A Phase 1a/1b Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies Ended

2023-504400-29-00 Phase I 1 country
An Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants With Advanced Malignancies Previously Enrolled in… Ended

2023-503406-36-00 Phase II 1 country PEMIGATINIB
A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inop… Ended

2024-512331-72-00 Phase III 8 countries CARBOPLATIN; PACLITAXEL; RETIFANLIMAB
A Randomized, Double Blind, Phase 3 Study of Platinum-Based Chemotherapy With or Without INCMGA00012 in First-Line Metastatic Squamous and N… Ended

2022-501987-16-00 Phase III 2 countries CARBOPLATIN; CISPLATIN; PACLITAXEL; PACLITAXEL ALBUMIN-BOUND; PEMETREXED; PEMETR…
A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabin… Ended

2024-513513-12-00 Phase III 8 countries CISPLATIN; GEMCITABINE; PEMIGATINIB
A Phase 3 randomized clinical Study of Pembrolizumab plus epacadostat, pembrolizumab monotherapy, and the EXTREME regimen as first line trea… Ended

2024-512015-47-00 Phase III 2 countries EPACADOSTAT; PEMBROLIZUMAB
Pembrolizumab (MK-3475) plus Epacadostat vs SoC in mRCC Ended

2024-512016-22-00 Phase III 1 country PEMBROLIZUMAB; SUNITINIB
A Phase I Study of INCB099280 in Combination With Ipilimumab in Participants With Selected Solid Tumors Ended

2023-503243-34-00 Phase I (Other) 3 countries INCB099280; IPILIMUMAB

Showing 49–59 of 59 trials

← All sponsors A–Z